/

Società

Ne

Non verificato

Neurotech Pharmaceuticals, Inc.

Di cosa scriviamo

BiotecnologiaFarmaceuticaIndustriaOtticaSalute

8 comunicati stampa

Guarda tutti i comunicati

02/06/2026

Industria

Oncologia

Scuola/Istruzione

Salute

Farmaceutica

Biotecnologia

Neurotech Launches “Uncovering MacTel” YouTube Channel to Support Patient Education and Awareness

Fonte

Neurotech Pharmaceuticals, Inc.

Emittente

1.00

0

12/03/2026

Industria

Scienza

Igiene alimentare

Biotecnologia

Salute

Farmaceutica

Ottica

Neurotech Provides Corporate Update on Commercial Progress

Fonte

Neurotech Pharmaceuticals, Inc.

Emittente

1.00

0

29/09/2025

Biotecnologia

Salute

Farmaceutica

Ottica

Industria

Neurotech Granted Permanent J-Code (J3403) for ENCELTO™ (revakinagene taroretcel-lwey), Effective October 1, 2025

Fonte

Neurotech Pharmaceuticals, Inc.

Emittente

1.00

0

02/09/2025

Neurotech Appoints Peter J. McDonnell, M.D., to the Company’s Board of Directors

Fonte

Neurotech Pharmaceuticals, Inc.

Emittente

1.00

0

11/08/2025

Salute

Igiene alimentare

Attrezzature medico-sanitarie

Farmaceutica

Ottica

Biotecnologia

Industria

First FDA-Approved Treatment for MacTel Performed

Fonte

Neurotech Pharmaceuticals, Inc.

Emittente

1.00

0

21/04/2025

Neurotech Appoints Beth Marsh as Chief Commercial Officer

Fonte

Neurotech Pharmaceuticals, Inc.

Emittente

1.00

0

06/03/2025

Industria

Igiene alimentare

Salute

Farmaceutica

Ottica

Biotecnologia

Neurotech’s ENCELTO™ (revakinagene taroretcel-lwey) Approved by the FDA for the Treatment of Macular Telangiectasia Type 2 (MacTel)

Fonte

Neurotech Pharmaceuticals, Inc.

Emittente

1.00

0

08/11/2024

Industria

Salute

Igiene alimentare

Medicina - Varie

Farmaceutica

Ottica

Biotecnologia

Neurotech Provides Update on BLA for NT-501 as a Treatment for Macular Telangiectasia Type 2 (MacTel)

Fonte

Neurotech Pharmaceuticals, Inc.

Emittente

1.00

0

Seguaci

0

Compatibilità

0